Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on June 11, 2020. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The filing discloses a specific financial event occurring on the report date.
Key Financial Metrics
The filing details a new borrowing event but does not provide comprehensive financial statements such as revenue, profit, or cash flow for a reporting period.
- New Debt Obligation: $1.0 million borrowed on June 11, 2020.
- Facility Type: Secured Convertible Facility Agreement with Juvenescence Limited.
- Maturity Date: March 30, 2023.
- Revenue/Profit/Margins: The filing text does not provide a clear value for these metrics.
- Liquidity: The filing text does not provide a clear value for overall liquidity positions beyond the new loan drawdown.
Material Changes
The primary material change is the creation of a direct financial obligation. On June 11, 2020, the company utilized available credit under an existing facility dated March 30, 2020, to secure an additional $1.0 million in funding. This increases the outstanding principal balance due to Juvenescence Limited.
Outlook, Risks, and Contingencies
Management Commentary: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors.
Risks and Contingencies: The loan agreement contains extensive "Events of Default" that could trigger immediate repayment of the outstanding principal. These include:
- Failure to make payments or perform obligations within 10 business days of notice.
- Incurrence of other indebtedness exceeding $100,000 becoming due early, or indebtedness over $25,000 not paid when due.
- Insolvency, liquidation, or inability to pay debts as they become due.
- Material adverse changes in financial condition or loss of material assets.
- Invalidity of security interests or loss of collateral.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Secured Convertible Facility Agreement with Juvenescence Limited following this $1.0 million drawdown.
- Review the terms of the "Secured Convertible Facility Agreement" to understand conversion rights and interest rates, which are not detailed in this 8-K.
- Assess the company's current cash runway and ability to service this debt given the strict default triggers regarding other indebtedness.
- Confirm the status of the collateral pledged under the Security Agreement referenced in the filing.